Latest California Healthline Stories
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
Podcast: KHN’s ‘What The Health?’ Reading The Tea Leaves In Blue Wave’s Wake
In this episode of KHN’s “What the Health?” Mary Agnes Carey of Kaiser Health News, Margot Sanger-Katz of The New York Times, Alice Ollstein of Politico and Anna Edney of Bloomberg News discuss the impact of House Democratic leadership elections and their impact on health policy; as well as efforts by the Trump administration to address high drug prices and ensure the safety of medical devices. Plus, Julie Rovner interviews KHN’s Jay Hancock about the latest “Bill of the Month.”
Podcast: KHN’s ‘What The Health?’ Health Nerd Books For The Holidays
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Stephanie Armour of The Wall Street Journal, Joanne Kenen of Politico and Anna Edney of Bloomberg News discuss the latest on open enrollment for the Affordable Care Act and Medicare; new moves by the Food and Drug Administration to regulate tobacco and nicotine products; and whether House Democrats will pursue a “Medicare-for-all” bill in the next Congress. Plus, for extra credit, the panelists recommend their favorite health policy books for your holiday reading and gifting pleasure.
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
New Heart Drug Spotlights Troubling Trends In Drug Marketing
Critics worry the marketing of Vascepa, a purified fish oil product, could prove a fish story.
Hidden Drugs And Danger Lurk In Over-The-Counter Supplements, Study Finds
Dieters and gym rats, beware. Some dietary supplements promising weight loss or more muscle may contain active ingredients not listed on the label that fly under the radar of the Food and Drug Administration. The California Department of Public Health analyzed public data maintained by the FDA to suss out trends among tainted products, raising red flags.
Podcast: KHN’s ‘What The Health?’ Falling Premiums And Rising Political Tensions
In this episode of KHN’s “What the Health?” Mary Agnes Carey of Kaiser Health News, Rebecca Adams of CQ Roll Call, Anna Edney of Bloomberg News and Julie Appleby of Kaiser Health News discuss the Trump administration’s announcement that average premium prices are falling on the Obamacare marketplaces, the effort by Senate Democrats to reverse rules on short-term health insurance and the focus on protections for people with preexisting conditions in the run-up to midterm elections.
The Feds’ Termination Of A Tiny Contract Inflames Bitter Fight Over Fetal Tissue
Just weeks before midterm elections, a move by federal health officials spotlights a contentious issue: the use of human fetal tissue in research. Here’s what you need to know to understand the debate.
Podcast: KHN’s ‘What The Health?’ Some Things Old, Some Things New
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Rebecca Adams of CQ Roll Call, Margot Sanger-Katz of The New York Times and Kimberly Leonard of the Washington Examiner discuss final action on bills in Congress to address the opioid epidemic and fund federal health agencies. They also look at new efforts by the Food and Drug Administration to crack down on teen nicotine use.
Drugmakers Play The Patent Game To Lock In Prices, Block Competitors
Pharmaceutical companies like Purdue Pharma, maker of OxyContin, often win patents for incremental changes with debatable value. Now there’s a twist involving an opioid treatment.